These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

874 related items for PubMed ID: 28886175

  • 21. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Chen X, Xu Z, Wu C, Xie L, Wang P, Liu X.
    Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
    [Abstract] [Full Text] [Related]

  • 22. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
    Escudier B, Powles T, Motzer RJ, Olencki T, Arén Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK.
    J Clin Oncol; 2018 Mar 10; 36(8):765-772. PubMed ID: 29309249
    [Abstract] [Full Text] [Related]

  • 23. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators.
    Lancet Oncol; 2016 Jul 10; 17(7):917-927. PubMed ID: 27279544
    [Abstract] [Full Text] [Related]

  • 24. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators.
    N Engl J Med; 2015 Nov 05; 373(19):1814-23. PubMed ID: 26406150
    [Abstract] [Full Text] [Related]

  • 25. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
    Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N.
    Clin Genitourin Cancer; 2016 Apr 05; 14(2):153-9. PubMed ID: 26781820
    [Abstract] [Full Text] [Related]

  • 26. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
    Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, CheckMate 025 investigators.
    Eur Urol; 2017 Dec 05; 72(6):962-971. PubMed ID: 28262413
    [Abstract] [Full Text] [Related]

  • 27. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I, Wells JC, Graham J, Yuasa T, Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC.
    Curr Oncol; 2019 Apr 05; 26(2):e175-e179. PubMed ID: 31043824
    [Abstract] [Full Text] [Related]

  • 28. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B.
    Cancer Treat Rev; 2016 Nov 05; 50():109-117. PubMed ID: 27664394
    [Abstract] [Full Text] [Related]

  • 29. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I, Poprach A, Zemánková A, Büchler T, Bartoš J, Šámal V, Študentová H, Rozsypalová A, Dvořák J, Brom O, Melichar B.
    Klin Onkol; 2021 Nov 05; 34(5):392-400. PubMed ID: 34915708
    [Abstract] [Full Text] [Related]

  • 30. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
    Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK.
    Br J Cancer; 2018 May 05; 118(9):1176-1178. PubMed ID: 29576624
    [Abstract] [Full Text] [Related]

  • 31. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.
    Eur Urol; 2011 Dec 05; 60(6):1163-70. PubMed ID: 21802830
    [Abstract] [Full Text] [Related]

  • 32. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G, Generali D.
    Eur Urol; 2017 Dec 05; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract] [Full Text] [Related]

  • 33. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
    Kucharz J, Dumnicka P, Kusnierz-Cabala B, Demkow T, Wiechno P.
    Med Oncol; 2019 Jan 21; 36(2):19. PubMed ID: 30666498
    [Abstract] [Full Text] [Related]

  • 34. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
    Tannir NM, Schwab G, Grünwald V.
    Curr Oncol Rep; 2017 Feb 21; 19(2):14. PubMed ID: 28247252
    [Abstract] [Full Text] [Related]

  • 35. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B, Rini BI, Motzer RJ, Tarazi J, Kim S, Huang X, Rosbrook B, English PA, Loomis AK, Williams JA.
    Clin Genitourin Cancer; 2015 Aug 21; 13(4):328-337.e3. PubMed ID: 25816720
    [Abstract] [Full Text] [Related]

  • 36. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C.
    Eur Urol Oncol; 2023 Jun 21; 6(3):339-348. PubMed ID: 36842942
    [Abstract] [Full Text] [Related]

  • 37. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
    Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.
    Clin Genitourin Cancer; 2016 Apr 21; 14(2):160-7.e3. PubMed ID: 26707954
    [Abstract] [Full Text] [Related]

  • 38. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
    Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B.
    Eur Urol; 2014 Apr 21; 65(4):713-20. PubMed ID: 23993162
    [Abstract] [Full Text] [Related]

  • 39. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.
    Eur J Cancer; 2019 Feb 21; 108():33-40. PubMed ID: 30616146
    [Abstract] [Full Text] [Related]

  • 40. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.
    Br J Cancer; 2014 Jun 10; 110(12):2821-8. PubMed ID: 24823696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.